zeneca zd 6169 has been researched along with labetalol in 1 studies
Studies (zeneca zd 6169) | Trials (zeneca zd 6169) | Recent Studies (post-2010) (zeneca zd 6169) | Studies (labetalol) | Trials (labetalol) | Recent Studies (post-2010) (labetalol) |
---|---|---|---|---|---|
42 | 0 | 3 | 1,980 | 450 | 327 |
Protein | Taxonomy | zeneca zd 6169 (IC50) | labetalol (IC50) |
---|---|---|---|
Beta-2 adrenergic receptor | Homo sapiens (human) | 0.016 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.354 | |
Beta-1 adrenergic receptor | Homo sapiens (human) | 0.01 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.393 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.354 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.521 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.393 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.037 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.607 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.815 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
1 other study(ies) available for zeneca zd 6169 and labetalol
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |